Table 2 Laboratory and clinical characteristics of L-T4 treated vs untreated groups of THOP patients

Participant, n

36 (43.3)

47 (56.6)

Sex (Male)

23 (63.8)

30 (63.8)

0.996^a

GA, wk

28 (24–32)

31 (24–34)

 < 0.001^b

BW, g

1057 ± 300

1383 ± 488

 < 0.001^c

SGA

8 (22)

11 (23)

0.899^a

GA (group)

 < 0.001^a

 24–27 wk

16 (44.4)

10 (21.2)

 28–30 wk

15 (41.6)

13 (27.6)

 31–34 wk

5 (13.8)

24 (51)

Length of hospital stay, d

54 (21–121)

40 (10–131)

0.003^b

Euthyroid time, wk

4 (3–7)

4 (3–17)

0.020^b

FT4 ( ng/dl)

0.80 (0.31–1.58)

1.07 (0.73–1.44)

 < 0.001^b

TSH (mU/L)

3.92(0.99–10.62)

3.90 (0.25–10.64)

0.575^b

GA groups

FT4 (ng/dl)

TSH (mU/L)

FT4 (ng/dl)

TSH (mU/L)

24–27 wk

0.74 (0.31–1.19)

5.2(1.27–7.82)

0.81(0.73–1.44)

3.42(0.25–10.64)

28–30 wk

0.91 (0.42–1.58)

3.05(0.99–7.84)

1.04(0.73–1.19)

3.47(1.25–10.6)

31–34 wk

1.06 (0.78–1.23)

3.92(2.59–7.50)

1.16(0.91–1.36)

4.11(0.88–9.08)

p value

0.093^d

0.301^d

0.001^d,^e

0.710^d